Scisparc Ltd. (SPRC) — 6-K Filings

6-K Filings (50)

• 6-K Filing — May 11, 2026
• SciSparc Ltd. Changes Certifying Accountant — Dec 31, 2025 Risk: low
  On December 9, 2025, SciSparc Ltd.'s Audit Committee recommended the cessation of services with its current certifying accountant. This change was subsequently
• 6-K Filing — Dec 2, 2025
• 6-K Filing — Nov 28, 2025
• 6-K Filing — Nov 26, 2025
• SciSparc & Clearmind Patent for Depression Treatment — Nov 20, 2025 Risk: medium
  On November 20, 2025, SciSparc Ltd. announced that its subsidiary, Neurothera Labs, filed an Israeli patent application in collaboration with Clearmind Medicine
• 6-K Filing — Nov 18, 2025
• SciSparc Closes TSXV Acquisition, Transfers Pharma Portfolio — Oct 27, 2025 Risk: medium
  On October 24, 2025, SciSparc Ltd. announced the closing of its acquisition of a publicly traded company on the TSXV. Through this acquisition, SciSparc transfe
• SciSparc Ltd. Files October 2025 Report (6-K) — Oct 24, 2025 Risk: low
  On February 25, 2025, SciSparc Ltd. entered into a Securities Purchase and Exchange Agreement with MitoCareX Bio Ltd. This filing is a Report of Foreign Private
• SciSparc & Clearmind Patent Targets Binge Disorders — Oct 20, 2025 Risk: medium
  On October 20, 2025, SciSparc Ltd. announced a collaboration with Clearmind that resulted in the publication of a U.S. patent application. This application targ
• SciSparc Ltd. Signs Asset and Share Purchase Agreement — Oct 15, 2025 Risk: medium
  On October 9, 2025, SciSparc Ltd. entered into an asset and share purchase agreement with Miza III Ventures Inc. This agreement involves the acquisition of asse
• SciSparc Ltd. Signs Framework Agreement for Potential Merger — Oct 6, 2025 Risk: medium
  On October 6, 2025, SciSparc Ltd. announced a framework agreement with AutoMax Motors Ltd. and SciSparc Merger Sub Ltd. to potentially merge. The agreement outl
• SciSparc Subsidiary Merger Approved by N2OFF Shareholders — Sep 30, 2025 Risk: medium
  SciSparc Ltd. announced on September 29, 2025, that N2OFF shareholders approved a merger with SciSparc's majority-owned subsidiary, MitoCareX. MitoCareX is a dr
• SciSparc Ltd. Seeks Warrant Exercise — Sep 26, 2025 Risk: medium
  On September 26, 2025, SciSparc Ltd. entered into inducement offer letter agreements with holders of its existing warrants. These agreements aim to encourage th
• SciSparc Ltd. Appoints New President — Sep 25, 2025 Risk: low
  On September 21, 2025, SciSparc Ltd. announced changes in its management. The board of directors resolved to appoint Amitay Weiss, previously the chairman, as t
• SciSparc Ltd. Reports Court Motion by AutoMax Motors Ltd. — Sep 16, 2025 Risk: medium
  On September 16, 2025, SciSparc Ltd. reported that AutoMax Motors Ltd. filed a motion with the Jerusalem District Court concerning the approval of certain actio
• SciSparc Ltd. Updates on AutoMax Motors Investigation — Sep 8, 2025 Risk: medium
  SciSparc Ltd. is reporting on an update from AutoMax Motors Ltd. On September 7, 2025, investigators from the Israeli Securities Authority and police searched t
• SciSparc Ltd. Files August 2025 6-K Report — Aug 29, 2025 Risk: low
  SciSparc Ltd. filed a Form 6-K on August 29, 2025, reporting on its activities for August 2025. This filing references a previous report from February 27, 2025,
• SciSparc Shareholders Approve Merger with Vehicle Importer — Aug 28, 2025 Risk: medium
  On August 28, 2025, SciSparc Ltd. announced that its shareholders approved a merger with a leading parallel vehicle importer in Israel. The company's principal
• SciSparc Ltd. Shareholders Approve All Proposals at Meeting — Aug 26, 2025 Risk: low
  SciSparc Ltd. announced on August 26, 2025, that its shareholders approved all proposals at the adjourned special general meeting. The company, formerly known a
• SciSparc Meeting Adjourned Due to Lack of Quorum — Aug 25, 2025 Risk: medium
  SciSparc Ltd. convened its Special General Meeting of Shareholders on August 25, 2025, but it was adjourned for one day due to a lack of quorum. The meeting wil
• SciSparc & Clearmind Patent for Obesity/Diabetes Therapy — Aug 8, 2025 Risk: medium
  SciSparc Ltd. announced on August 7, 2025, a collaboration with Clearmind that has led to the publication of an international patent application. This applicati
• SciSparc Files International Patent for Weight Loss Therapy — Jul 31, 2025 Risk: medium
  On July 30, 2025, SciSparc Ltd. announced the filing of an international patent application for a novel combination therapy targeting weight loss and fatty live
• SciSparc Regains Nasdaq Minimum Bid Price Compliance — Jul 22, 2025 Risk: medium
  On July 22, 2025, SciSparc Ltd. announced it has regained compliance with the Nasdaq minimum bid price requirement. This means the company's stock price has sta
• SciSparc Ltd. Shareholders Approve All Proposals at AGM — Jun 26, 2025 Risk: low
  SciSparc Ltd. announced on June 26, 2025, that its shareholders approved all proposals at the adjourned annual general meeting. The company, formerly known as T
• SciSparc Annual Meeting Adjourned Due to Lack of Quorum — Jun 25, 2025 Risk: low
  SciSparc Ltd. convened its Annual General Meeting of Shareholders on June 25, 2025, but it was adjourned for one day due to a lack of quorum. The meeting will r
• SciSparc Ltd. Announces 1-for-21 Reverse Share Split — Jun 24, 2025 Risk: medium
  On June 24, 2025, SciSparc Ltd. announced a 1-for-21 reverse share split. This action is intended to increase the per-share market price of its ordinary shares.
• SciSparc Ltd. Files 6-K, References Merger Agreement — Jun 9, 2025 Risk: medium
  SciSparc Ltd. filed a Form 6-K on June 9, 2025, referencing a prior filing from April 11, 2024. This current filing is related to an agreement and plan of merge
• SciSparc Ltd. Announces Japanese Patent Application Publication — May 27, 2025 Risk: low
  On May 27, 2025, SciSparc Ltd. announced the publication of a Japanese patent application related to its core technology. This filing, Report No. 3 for May 2025
• SciSparc Ltd. Announces Annual General Meeting Date — May 21, 2025 Risk: low
  SciSparc Ltd. filed a Form 6-K on May 21, 2025, to report its Notice of Annual General Meeting of Shareholders, Proxy Statement, and Proxy Card. The meeting is
• SciSparc & Clearmind Patent for Cocaine Addiction Therapy — May 13, 2025 Risk: medium
  On May 12, 2025, SciSparc Ltd. announced a significant development in their collaboration with Clearmind, resulting in the publication of a European Patent. Thi
• SciSparc Files International Patent for Eating Disorder Treatment — Apr 25, 2025 Risk: medium
  On April 25, 2025, SciSparc Ltd. announced the filing of an international patent application for a novel treatment of eating disorders, including anorexia and b
• SciSparc Ltd. Amends Merger Agreement — Apr 1, 2025 Risk: medium
  SciSparc Ltd. announced on March 27, 2025, a third addendum to its Agreement and Plan of Merger, originally dated April 11, 2024. This filing is a report of a f
• SciSparc & Clearmind Patent for Cocaine Addiction — Mar 11, 2025 Risk: medium
  SciSparc Ltd. announced on March 10, 2025, that its collaboration with Clearmind has led to the publication of a patent application in South Korea for a psyched
• SciSparc Ltd. Acquires MitoCareX Bio Ltd. — Mar 3, 2025 Risk: medium
  On February 25, 2025, SciSparc Ltd. entered into a Securities Purchase and Exchange Agreement with MitoCareX Bio Ltd. This agreement involves the acquisition of
• SciSparc Ltd. Sells Convertible Securities to Investors — Feb 27, 2025 Risk: medium
  On February 25, 2025, SciSparc Ltd. entered into securities purchase agreements to sell and issue convertible securities to certain investors. The filing does n
• SciSparc Secures Favorable Lawsuit Settlement — Feb 18, 2025 Risk: low
  On February 18, 2025, SciSparc Ltd. announced a favorable settlement in a lawsuit it initiated. The company will receive cash compensation and a full release fr
• SciSparc & Clearmind Patent for Binge Behavior Treatment in Mexico — Feb 4, 2025 Risk: medium
  On February 4, 2025, SciSparc Ltd. announced a collaboration with Clearmind that resulted in the publication of a patent for a binge behavior combination treatm
• SciSparc Gets 180-Day Nasdaq Bid Price Compliance Extension — Jan 15, 2025 Risk: medium
  SciSparc Ltd. announced on January 15, 2025, that it has received an 180-day extension from the Nasdaq Stock Market LLC to regain compliance with the minimum bi
• SciSparc & Clearmind Patent for Binge Behavior Treatment — Jan 7, 2025 Risk: medium
  On January 6, 2025, SciSparc Ltd. announced a collaboration with Clearmind Medicine regarding the publication of a European patent application. This application
• SciSparc Trial for Autism Gets Green Light — Dec 31, 2024 Risk: medium
  On December 31, 2024, SciSparc Ltd. announced the renewal of approval from the Israeli Medical Cannabis Agency for its clinical trial focused on children with A
• SciSparc Ltd. Updates on AutoMax Motors' $13M Vehicle Delivery — Dec 26, 2024 Risk: medium
  On December 26, 2024, SciSparc Ltd. reported on AutoMax Motors Ltd.'s announcement of its first delivery of JAC vehicles, valued at $13 million. This delivery f
• SciSparc Updates Spin-off of Pharma Portfolio — Dec 17, 2024 Risk: medium
  On December 16, 2024, SciSparc Ltd. announced updates regarding the spin-off of its advanced clinical-stage pharmaceutical portfolio into a publicly traded comp
• SciSparc Ltd. Files November 2024 6-K Report — Nov 29, 2024 Risk: low
  SciSparc Ltd. filed a Form 6-K on November 29, 2024, referencing a prior 6-K from April 11, 2024. The filing is a Report of Foreign Private Issuer for the month
• SciSparc Ltd. Amends Merger Agreement — Nov 27, 2024 Risk: medium
  SciSparc Ltd. announced on November 26, 2024, a second addendum to its Agreement and Plan of Merger, originally dated April 11, 2024. This addendum modifies the
• SciSparc Ltd. Files 6-K Report — Nov 4, 2024 Risk: low
  SciSparc Ltd. filed a Form 6-K on November 4, 2024, reporting information as of June 30, 2024. The filing is a Report of Foreign Private Issuer and indicates th
• SciSparc Ltd. Shareholders Approve All Proposals at AGM — Oct 23, 2024 Risk: low
  SciSparc Ltd. announced on October 23, 2024, that its shareholders approved all proposals at the adjourned annual general meeting. This includes the re-appointm
• SciSparc Annual Meeting Adjourned Due to Lack of Quorum — Oct 22, 2024 Risk: low
  SciSparc Ltd. convened its Annual General Meeting of Shareholders on October 22, 2024, but it was adjourned for one day due to a lack of quorum. The meeting wil
• SciSparc Ltd. Postpones Annual General Meeting — Sep 27, 2024 Risk: low
  SciSparc Ltd. announced on September 27, 2024, that its Annual General Meeting of Shareholders, originally scheduled for October 1, 2024, has been postponed. Th
• SciSparc to Sell Stake in MitoCareX — Sep 26, 2024 Risk: medium
  On September 26, 2024, SciSparc Ltd. announced it has signed a non-binding Letter of Intent to sell its stake in MitoCareX. The specific details of the stake an

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX